What type of study is this?

September 14, 2025

[Clinical Efficacy of CAG Regimen Combined with Venetoclax, Chidamide, and Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia].

View Full Paper

Ask AI

Bookmark

The overall response rate reached 93.3%, with 11 out of 15 patients achieving complete response after treatment.
Next-generation sequencing revealed gene mutations in 13 patients, with 12 having composite responses, indicating a correlation between mutations and efficacy.
Adverse events were primarily myelosuppression, with infections observed in 10 patients, suggesting manageable side effects associated with the regimen.
Median overall survival and event-free survival remained unreached within the follow-up period, highlighting the need for longer-term studies.

No takes yet. Share an insight, caveat, or question.

Clinical trial shows 93.3% overall response rate in elderly patients with acute myeloid leukemia, suggesting CAG regimen's potential.

Liu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark